If you don't mind a little risk in your IRA and who doesn't put this AMRS in there and talk to me in four years. With this crappola market who knows when this stock will perform but for a little bio there is so much going on with this company.
PUT AWAY- Amyris
Amyris assumed with an Outperform at Cowen 07:39 AMRS Cowen analyst Steven Mah assumed coverage of Amyris with an unchanged Outperform rating as he took over coverage of the Synthetic Biology space at the firm. Broadly defined, "SynBio" is a high-single digit trillion market that will grow to mid-double digit trillions by 2025, contends Mah.
PUT AWAY- Amyris
Amyris assumed with an Outperform at Cowen 07:39 AMRS Cowen analyst Steven Mah assumed coverage of Amyris with an unchanged Outperform rating as he took over coverage of the Synthetic Biology space at the firm. Broadly defined, "SynBio" is a high-single digit trillion market that will grow to mid-double digit trillions by 2025, contends Mah.